A new medicines trade and health security agenda for the European Commission

19 February 2021

In response to the European Commission Trade Communication published on […]

No further excuse to delay digital regulatory infrastructure for medicines after Covid-19 pandemic

19 February 2021

Smarter use of generic, biosimilar and value added medicines will ensure equitable access to cancer care

4 February 2021

AESGP, EFPIA and Medicines for Europe reflections on the European Medicines Agency, the Heads of Medicines Agencies and the European Commission “Key principles for the use of electronic product information for EU medicines” press release.

3 February 2021

Window of opportunity to enhance EU regulatory systems wide open as EU pharma strategy prioritises stronger EU networks

19 January 2021

EU digital strategy requires investments in the digitalisation of Europe’s medicines regulatory agencies to succeed

15 January 2021

EU Pharma Strategy: Success depends on access to Generic, Biosimilar and Value Added Medicines

25 November 2020

Failure to launch: white paper explores the role of inappropriate use of IP in blocking access to generic and biosimilar medicines

5 November 2020

Statement from the President: Now or never: pragmatism & ambition needed in EU pharma strategy to deliver on Europe’s medicines manufacturing

7 October 2020

Berlin, 07 October 2020, speaking at ‘For a Healthy Europe’, […]

COVID-19 a lightning rod for major overhaul of EU pharmaceutical policy

9 July 2020

Urgent call for a structured industry-EU dialogue on reform The […]